I'm LongbridgeAI, I can summarize articles.A wave of M&A and capital restructuring is accelerating across US mid-to-small-cap industrial and healthcare sectors in H2 2026, led by major acquisitions from IES Holdings and Stryker as firms secure capital for expansion.
Mergers, acquisitions, and strategic capital raises are accelerating across niche US industrial and healthcare sectors in the second half of 2026, with several mid-to-small-cap companies announcing significant deals to secure market share, according to industry data.
In the industrial and infrastructure space, IES Holdings (IESC.US) is targeting expanded scale with its August 2026 agreement to acquire DBM Global Inc. for approximately USD 670 million. The move follows a robust fiscal second quarter for IES, which saw revenue jump 17% to USD 974 million. According to people familiar with the broader infrastructure market, capital is increasingly flowing into integrated solutions. Similarly, Recon Technology (RCON.US) launched a USD 100 million equity offering program in July 2026, shortly before securing a USD 1.33 million IT contract in China. These expansion efforts contrast with the earlier privatization of logistics firm Patriot Transportation Holding (PTRN.US). Meanwhile, construction engineering firm Argan (AGX.US) and Japanese trading house ITOCHU Corporation (ITOCY.US) continue to monitor the evolving global industrial landscape.
The healthcare technology and biotech sectors are also experiencing a wave of strategic realignments. Medical device giant Stryker (SYK.US) announced a deal to acquire ZuriMED in August 2026, aiming to bolster its sports medicine portfolio. Stryker posted USD 6.6 billion in Q2 2026 revenue and raised the lower end of its full-year organic sales forecast to a target of 8.3% to 9.3%. On the biotech front, Verastem Oncology (VSTM.US) secured up to USD 75 million in non-dilutive royalty financing in August, reporting Q2 revenues of USD 40.1 million as it advances its RAMP 205 trial. Meanwhile, clinical-stage developer Artelo Biosciences (ARTL.US) implemented a 1-for-9 reverse stock split in late August, and INVO Bioscience (INIO.US) continues to navigate tight biotech funding markets.
In the energy transition sector, companies are aggressively pursuing cross-border volume. CBAK Energy Technology (CBAT.US) recently secured a USD 96 million battery order from an Indian EV manufacturer in August 2026. The battery maker is targeting full capacity at its designated facility through 2027, following a first quarter where net revenues surged 99.3% to USD 69.62 million.
This article does not constitute investment advice.